Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 11:05pm CEST
   By Debbie Cai 
 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SCICLONE PHARMACEUTICALS,
05/10 SCICLONE PHARMACEUTICALS : posts 1Q profit
05/10 SCICLONE PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
05/10 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Results of Operations ..
05/10 SCICLONE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
05/10 SCICLONE PHARMACEUTICALS : Reports First Quarter 2017 Financial Results
05/09 SCICLONE PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change ..
05/04 SCICLONE PHARMACEUTICALS : To Report First Quarter 2017 Financial Results On May..
03/27 SCICLONE PHARMACEUTICALS : To Present At Needham Healthcare Conference On April ..
03/20 SCICLONE PHARMACEUTICALS : How These Drug Makers Stocks are Faring? -- Orexigen ..
03/06 SCICLONE PHARMACEUTICALS, INC. (NASD : SCLN) Files An 8-K Results of Operations ..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/10 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q1 2017 Results - Ea..
05/10 SciClone Pharmaceuticals beats by $0.17, beats on revenue
03/06 SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Ea..
03/06 SciClone Pharmaceuticals reports Q4 results
02/02 SCICLONE PHARMACEUTICALS : Beyond The Death Of A Sales Process
Advertisement
Financials ($)
Sales 2017 174 M
EBIT 2017 51,1 M
Net income 2017 49,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 10,16
P/E ratio 2018 8,58
Capi. / Sales 2017 2,78x
Capi. / Sales 2018 2,61x
Capitalization 484 M
More Financials
Chart SCICLONE PHARMACEUTICALS,
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Full-screen chart
Technical analysis trends SCICLONE PHARMACE...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 14,0 $
Spread / Average Target 50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Cheung Chief Financial Officer & Senior VP-Finance
Richard J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SCICLONE PHARMACEUTICA..-13.43%484
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results